FDA Approves Rocket Pharmaceuticals' Kresladi Gene Therapy for Rare LAD-1 Immune Disorder
FDA approves Kresladi gene therapy for LAD-1 after positive results in a single-arm study of only nine patients; highlights small sample size and industry sponsorship.
The U.S. Food and Drug Administration has approved Kresladi, a gene therapy developed by Rocket Pharmaceuticals, for the treatment of leukocyte adhesion deficiency type 1 (LAD-1), a rare and severe immune disorder. The approval was granted based on data from a small study involving only nine patients that showed positive clinical results. Given the ultra-rare nature of the condition, the evidence comes from a limited single-arm trial rather than a randomized controlled trial (RCT). Sample size is noted as n=9 with no peer-reviewed publication details provided in the source. As an industry-sponsored therapy, potential conflicts of interest exist due to Rocket Pharmaceuticals' financial stake in the outcome. This marks another advance in gene therapy for rare diseases but underscores the reliance on small observational datasets for regulatory decisions in areas of high unmet need. Source: https://www.statnews.com/2026/03/26/rocket-pharma-kresladi-lad-1-fda-approval/?utm_campaign=rss
VITALIS: This approval signals that even rare conditions affecting just a handful of families can finally get real treatment options instead of lifelong hospital visits. For ordinary people it means the door is opening wider for personalized fixes to diseases that used to have no hope, even when the evidence starts small.
Sources (1)
- [1]STAT+: FDA approves Rocket gene therapy for rare immune disorder(https://www.statnews.com/2026/03/26/rocket-pharma-kresladi-lad-1-fda-approval/?utm_campaign=rss)